Swedish drugmaker Swedish Orphan Biovitrum (Sobi) reported second-quarter results that topped analyst expectations, prompting Berenberg to raise its forecasts and price target on the stock. The investment bank now sees stronger revenue growth ahead, driven by demand for Sobi's core medicines.
Strong Quarter, Higher Forecasts
Sobi posted 29% organic revenue growth for the three months ended June, above the 22% consensus that Berenberg had been using. The beat was broad-based, with the bank noting that demand across Sobi's key product lines was robust. In response, Berenberg raised its 2026 organic growth assumption to 22% and lifted its sales, profit, and earnings-per-share forecasts through 2028.
The bank also increased its price target on the stock, though it did not specify the new target in the brief. Berenberg now values Sobi at 18.8 times estimated 2027 earnings and 15.6 times estimated 2028 earnings, suggesting the stock is not expensive relative to its growth prospects.
Management's Conservative Guidance
Berenberg noted that Sobi's own guidance implies growth slowing to the low double digits in the second half of the year. However, the bank views this as typical conservatism from management rather than a sign that the business is stalling. Many companies in the pharmaceutical sector tend to set cautious initial guidance to leave room for upside surprises, and Sobi appears to be following that pattern.
The debate among analysts now centers on whether longer-term numbers need to catch up to the latest run rate. When a company delivers a clear beat, analysts often revise their models higher: first revenue, then profit, then earnings per share. As those forward earnings estimates rise, the stock's forward price-to-earnings ratio can fall mechanically even if the share price barely moves, which can make a valuation look less stretched on paper.
What It Means for Investors
For everyday investors, the key takeaway is that Sobi's strong quarter has reset expectations. The 29% growth rate versus the 22% consensus is a significant beat, and it suggests that the company's core medicines are gaining traction. If more brokers follow Berenberg's lead and lift their profit forecasts, the stock's valuation could become even more attractive.
Berenberg's framing of Sobi at 18.8 times 2027 earnings and 15.6 times 2028 earnings already suggests the stock is reasonably priced. If other analysts raise their forecasts, those multiples would drop further unless the shares reprice higher. That dynamic tends to create room for higher price targets without needing a bigger valuation multiple.
Investors should also watch for any updates from Sobi's management on second-half trends. If the company confirms that growth is indeed slowing to the low double digits, the stock could face headwinds. But if the company delivers another beat, the positive momentum could continue.
For context, other companies that have recently reported strong quarters have seen similar analyst upgrades. For example, Danske Bank lifted its profit forecast after a strong Q2 beat, and Berenberg raised ASML's price target after stronger 2026 margin guidance. These patterns show how a single quarter can shift the narrative for a stock.
Ultimately, Sobi's Q2 results have given investors a reason to be more optimistic. The company's strong revenue growth and Berenberg's upgraded forecasts suggest that the stock could have further upside, especially if the broader market remains supportive of growth stocks.
